Welcome to our dedicated page for Synlogic news (Ticker: SYBX), a resource for investors and traders seeking the latest updates and insights on Synlogic stock.
Synlogic, Inc. (Nasdaq: SYBX) is a clinical-stage biopharmaceutical company at the forefront of synthetic biology and microbiome research. The company is pioneering the development of Synthetic Biotics™, which are engineered probiotic bacteria designed to perform specific therapeutic functions. These innovative biotherapeutics target a range of metabolic and rare genetic diseases, addressing unmet medical needs.
Using its proprietary Synthetic Biotics™ platform, Synlogic engineers probiotics to correct metabolic dysfunctions linked to various diseases. These therapeutics are primarily delivered orally, acting from the gut microbiome to address systemic issues. The company’s lead programs include treatments for rare genetic metabolic disorders such as phenylketonuria (PKU) and homocystinuria (HCU). Synlogic's pipeline also targets conditions like enteric hyperoxaluria, gout, and cystinuria.
One of Synlogic's flagship projects, labafenogene marselecobac (SYNB1934), is currently in a global, pivotal Phase 3 study for PKU, known as Synpheny-3. Additional candidates, such as SYNB1353 for HCU, are also progressing through clinical stages. The company collaborates with notable partners including Roche for inflammatory bowel disease (IBD) research and Ginkgo Bioworks for synthetic biology advancements.
Synlogic's commitment to innovative medicine is further demonstrated by its recent achievements. In December 2023, the company announced that SYNB1353, a potential treatment for HCU, would be presented at the International Conference on Microbiome Engineering. Additionally, Synlogic secured a $1 million subcontract from the Air Force Research Lab to develop a manufacturing process for a potential live probiotic product, extending a project initiated in 2020.
The company’s approach leverages well-characterized probiotics, such as Escherichia coli Nissle 1917, ensuring consistency, safety, and non-colonizing properties, which simplify oral administration and storage. Synlogic continues to expand its pipeline and research capabilities, driving forward its mission to transform the care of serious diseases through groundbreaking synthetic biology technologies.
Synlogic, Inc. (SYBX) announced its fourth-quarter and full-year 2022 financial results, highlighting significant advancements in its pipeline for treating phenylketonuria (PKU) and homocystinuria (HCU). The company is on track to initiate its pivotal Phase 3 trial for SYNB1934 in PKU by mid-2023. Additionally, it received Rare Pediatric Disease Designation for SYNB1934 and SYNB1353. Financially, Synlogic reported revenues of $1.2 million for 2022, a decrease from $1.8 million in 2021, with a net loss of $66.1 million, or $0.92 per share. The company has $77.6 million in cash to support operations through the second half of 2024.
FAQ
What is the current stock price of Synlogic (SYBX)?
What is the market cap of Synlogic (SYBX)?
What does Synlogic, Inc. specialize in?
What are Synthetic Biotics™?
What is Synlogic’s lead program?
What diseases are covered by Synlogic's pipeline?
How does Synlogic deliver its Synthetic Biotics™?
Who are Synlogic's research partners?
What recent achievements has Synlogic announced?
What makes Synlogic's probiotics unique?
What is SYNB1353 aimed at treating?
Where can I find more information about Synlogic?
